Burger line Burger line Burger line
Logo Logo Logo
Burger line Burger line Burger line
Sign in
Sign in

FDA Approves Briumvi for Relapsing Multiple

FDA Approves Briumvi for Relapsing Multiple

Ublituximab-xiiy from TG Therapeutics Inc is the first anti-CD20 monoclonal antibody approved for individuals with RMS that is administered as a 1-hour infusion after the starting dose.

The FDA has approved ublituximab-xiiy (Briumvi; TG Therapeutics Inc) for the treatment of relapsing multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

Ublituximab-xiiy is the first anti-CD20 monoclonal antibody approved for individuals with RMS that can be administered as a 1-hour intravenous (IV) infusion after the starting dose. The starting dose consists of 150 mg of ublituximab-xiiy administered in 4 hours, followed by an infusion of 450 mg administered in 1 hour on day 15. Afterward, the drug is administered in the 450-mg dosage in 1 hour every 24 weeks.

“The outcome of the ULTIMATE I & II trials evaluating ublituximab, a novel targeted anti-CD20 agent designed for efficient B-cell depletion that supported this approval, represents an important milestone in the history of MS research as the first phase 3 study of an anti-CD20 monoclonal antibody in patients with relapsing MS to produce an annualized relapse rate of less than 0.10, which translates to less than 1 relapse in 10 years,” Lawrence Steinman, MD, professor of Neurology and Neurological Sciences and Pediatrics at Stanford University, said in a statement. “This approval is great news for patients living with MS and provides an appealing treatment alternative that can be administered in a 1-hour infusion twice-a-year following the starting dose, which I believe is an added benefit to patients.”.

ULTIMATE 1 (NCT03277261) and 2 (NCT03277248) are double-blinded, parallel-group, randomized clinical trials that have identical designs. The studies were intended to include individuals with RMS who were treated for 96 weeks.

They were randomized to receive either ublituximab-xii, as an infusion of 150 mg in 4 hours, then 450 mg in 1 hour 2 weeks after the first infusion, and then 450 mg every 24 weeks in 1 hour, or teriflunomide, an active comparator, which was given orally as a 14-mg daily dose with an intravenous placebo on the same schedule as ublituximab-xii.

Investigators enrolled individuals who had experienced at least 1 relapse in the previous year, 2 relapses in the previous 2 years, or had T1 gadolinium (Gd)-enhancing lesions that were present in the previous year. Further, individuals were also required to have an Expanded Disability Status Scale score between 0 and 5.5 at baseline.

The 2 trials had a total of 1094 individuals across 10 countries.

“The approval of [ublituximab-xii] is wonderful news. MS is most frequently diagnosed during the prime of a person’s life when they are just starting a career or beginning a family,” June Halper, MSN, APN-C, MSCN, FAAN, CEO of Consortium of Multiple Sclerosis Centers, said in the statement.

“The availability of anti-CD20s has launched a new era of high efficacy therapies for [MS],” she said.

Investigators found that annualized relapses in the ULTIMATE 1 trail were 0.076 for those on ublituximab-xii and 0.188 for those on teriflunomide. In ULTIMATE 3, they found 0.091 and 0.178, respectively.

The proportion of individuals with 12-week confirmed disability progression, calculated for both studies, was 5.2% for ublituximab-xii and 5.9% for teriflunomide.

Additionally, the mean number of T1 Gd-enhancing lesions per MRI were 0.016 for ublituximab-xii in ULTIMATE 1 and 0.491 for teriflunomide. For ULTIMATE 2, investigators found 0.009 and 0.250, respectively.


TG Therapeutics announces FDA approval of Briumvi (ublituximab-xiiy). TG Therapeutics. News release. December 28, 2022. Accessed January 5, 2023. https://ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-announces-fda-appro...

January 6, 2023


0
Cart Subtotal:
Go to cart
You will be able to Pay Online or Request a Quote